{
    "clinical_study": {
        "@rank": "14970", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 (FK949E low dose tablet-first group)", 
                "arm_group_type": "Experimental", 
                "description": "Days 1 and 2: One FK949E low dose tablet Days 3 to 6: Three FK949E low dose tablets Days 7 to 10: One FK949E high dose tablet"
            }, 
            {
                "arm_group_label": "Group 2 (FK949E high dose tablet-first group)", 
                "arm_group_type": "Experimental", 
                "description": "Days 1 and 2: One FK949E low dose tablet Days 3 to 6: One FK949E high dose tablet Days 7 to 10: Three FK949E low dose tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to compare the pharmacokinetics of FK949E low dose tablets and FK949E high\n      dose tablets in non-elderly patients with major depressive disorder. The safety of FK949E in\n      the population was also evaluated."
        }, 
        "brief_title": "Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The objective of the study is to compare the pharmacokinetics of FK949E low dose tablets and\n      FK949E high dose tablets in non-elderly patients with major depressive disorder in a 2 \u00d7 2\n      crossover design. The safety of FK949E in the population is also evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients considered to be able to understand and follow subject requirements, as\n             judged by the investigator/sub-investigator.\n\n          -  Patients diagnosed with major depressive disorder according to the DSM-IV-TR by means\n             of M.I.N.I.\n\n          -  BMI: 17.6 (inclusive) to 26.4 (exclusive).\n\n        Exclusion Criteria:\n\n          -  Current or past history of DSM-IV-TR Axis I disorder, except major depressive\n             disorder, within the past 6 months before informed consent.\n\n          -  Concurrent DSM-IV-TR Axis II disorder that is considered to greatly affect patient's\n             current mental status.\n\n          -  Current or past history of dependence of substances (other than caffeine and\n             nicotine) or history of abuse or dependence of alcohol.\n\n          -  Unable to suspend treatment with inducers or inhibitors of the drug-metabolizing\n             enzyme, cytochrome P450 3A4 (CYP3A4), for 14 days before the screening assessment and\n             throughout the study.\n\n          -  Patients who could not use an appropriate contraception (condoms) during the study.\n             Patients who were pregnant or lactating.\n\n          -  Patients (carriers) with documented or suspected renal failure, hepatic failure,\n             serious cardiac disease, hepatitis B, hepatitis C, or acquired immunodeficiency\n             syndrome (AIDS).\n\n          -  Patients receiving treatment for hypertension, or patients with concurrent\n             hypertension or unstable angina that may worsen with the study or may affect the\n             study results based on the clinical judgment of the investigator/sub-investigator.\n\n          -  Patients with concurrent hypotension (criterion for hypotension: a systolic blood\n             pressure of less than 100 mmHg), or orthostatic hypotension\n\n          -  Patients with a mean QTcF interval of \u2265450 ms on a 12-lead ECG at the screening\n             assessment\n\n          -  Patients with the risk of torsades de pointe (e.g., those with a history of QT\n             prolongation, those with familial long QT syndrome).\n\n          -  Concurrent malabsorption syndrome, hepatic disease, or other conditions that may\n             affect the absorption and/or metabolism of the study drug.\n\n          -  Concurrent malignancy or history of cured malignancy within 5 years\n\n          -  Current or past history of cerebrovascular disease or transient ischemic attack\n             (TIA).\n\n          -  Received electroconvulsive therapy within 90 days before the screening assessment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919008", 
            "org_study_id": "6949-CL-0006"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1 (FK949E low dose tablet-first group)", 
                "Group 2 (FK949E high dose tablet-first group)"
            ], 
            "description": "Oral", 
            "intervention_name": "FK949E", 
            "intervention_type": "Drug", 
            "other_name": "extended release formulation of quetiapine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Major Depressive Disorder", 
            "FK949E", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanto", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase I Study of FK949E - Comparison of Pharmacokinetics Between FK949E 50 mg Tablets and FK949E 150 mg Tablets in Patients With Major Depressive Disorder", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "Maximum plasma concentration (Cmax) of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "AUC24h (area under the curve for 24hr) of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919008"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "Trough value of plasma concentration of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "t1/2 of plasma concentration of unchanged quetiapine", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "Maximum plasma concentration (Cmax) of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "AUC (area under the curve) of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "trough value of plasma concentration of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "tmax of plasma concentration of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "description": "Frequent blood sampling on Day 6 and Day 10", 
                "measure": "t1/2 of plasma concentration of quetiapine metabolites", 
                "safety_issue": "No", 
                "time_frame": "For 24 hours after dosing"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 11"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}